BI
ACAD icon

Boulegeris Investments’s Acadia Pharmaceuticals ACAD Stock Holding History

Boulegeris Investments’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-60,720
Closed -$1.93M – 49
2014
Q4 		$1.93M Buy
60,720
+10,490
+21% +$297K 1.53% 18
2014
Q3 		$1.24M Buy
+50,230
New +$1.17M 1.01% 25

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return

Boulegeris Investments's ACAD Position: Q1 2015 in Review

Boulegeris Investments sold out of Acadia Pharmaceuticals (ACAD) in Q1 2015, closing a stake of 60,720 shares — an estimated $1.93M sold.

Boulegeris Investments first reported a position in ACAD in Q3 2014 and held it in 2 quarters. The position peaked at $1.93M in Q4 2014. 193 funds tracked by Wall St. Rank hold ACAD as of Q1 2015.

  • Boulegeris Investments reported no remaining Acadia Pharmaceuticals position as of Q1 2015 after selling out during the quarter.
  • Boulegeris Investments sold 60,720 Acadia Pharmaceuticals shares in Q1 2015, an estimated $1.93M.
  • Boulegeris Investments first reported a position in Acadia Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Boulegeris Investments's Acadia Pharmaceuticals position peaked at $1.93M in Q4 2014.
  • 193 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q1 2015.

Based on Boulegeris Investments's 13F filing for Q1 2015, filed 12 May 2015.